Brilinta has been approved to crush to administer for the first time as an antiplatelet drug
The AstraZeneca’s ‘Brilinta (generic name: ticagrelor)’ has been approved to administer in a crushed form by the Ministry of Food andDrug Safety for the first time as an antiplatelet drug.
It is observed that the approval will increase administering convenience of patients having a swallowing di...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
